IEQ Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

IEQ Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,048	Closed	-$123K	–	2160
2026 Q1	$123K	Hold	40,048	–	–	﹤0.01%	1772
2025 Q4	$164K	Buy	40,048 +6,000	+18%	+$29.7K	﹤0.01%	1722
2025 Q3	$166K	Hold	34,048	–	–	﹤0.01%	1709
2025 Q2	$172K	Sell	34,048 -19,180	-36%	-$94.2K	﹤0.01%	1643
2025 Q1	$282K	Buy	53,228 +19,180	+56%	+$140K	﹤0.01%	1217
2024 Q4	$230K	Hold	34,048	–	–	﹤0.01%	1142
2024 Q3	$224K	Hold	34,048	–	–	﹤0.01%	1027
2024 Q2	$255K	Hold	34,048	–	–	﹤0.01%	847
2024 Q1	$339K	Hold	34,048	–	–	﹤0.01%	739
2023 Q4	$336K	Buy	34,048 +7,168	+27%	+$51.1K	0.01%	701
2023 Q3	$206K	Buy	26,880 +8,960	+50%	+$89.4K	﹤0.01%	832
2023 Q2	$134K	Hold	17,920	–	–	﹤0.01%	834
2023 Q1	$120K	Hold	17,920	–	–	﹤0.01%	845
2022 Q4	$138K	Hold	17,920	–	–	﹤0.01%	756
2022 Q3	$191K	Buy	+17,920	New	+$181K	0.01%	775

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IEQ Capital's RXRX Position: Q2 2026 in Review

IEQ Capital sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 40,048 shares — an estimated $123K sold.

IEQ Capital first reported a position in RXRX in Q3 2022 and held it in 15 quarters. The position peaked at $339K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

IEQ Capital reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
IEQ Capital sold 40,048 Recursion Pharmaceuticals shares in Q2 2026, an estimated $123K.
IEQ Capital first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 15 quarters.
IEQ Capital's Recursion Pharmaceuticals position peaked at $339K in Q1 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.